TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05495542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker (Bionix, Toledo, OH) is one of the methods that can be used to reduce pain caused by IM injections. This small, flat, U-shaped plastic device used by holding it on the skin surface during injection did not have any side effects \[5\]. ShotBlocker has a surface of 2 mm thick with rounded nubs to stimulate the skin (Figure 1). The surface of the plastic device is placed on the skin just before the injection; there is a hole in the center where the injection is administered \[6\]. The rounded nubs on the surface of the plastic device do not damage the skin, these rounded nubs that create a slight pressure provide a warning for the Gate Control Theory \[7\]
Study: NCT02639949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral adherence promotion program
Description: A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study: NCT01170442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 2000 IU
Description: vitamin D3 2000 IU orally, daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 5000 IU
Description: vitamin D3 5000 IU orally, daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo orally, daily for six months
Study: NCT03656796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with auditory cues
Description: Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
Study: NCT03612934

Intervention type: PROCEDURE
Intervention: Specialist Palliative Care
Description: In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients

Intervention type: PROCEDURE
Intervention: Specialist Palliative Care
Description: In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
Study: NCT04822116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: goal directed intraoperative haemodynamic optimization
Description: all interventions that were pre-specified to be administered as part of the protocol
Study: NCT03656796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with auditory cues
Description: Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with auditory cues
Description: Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training without auditory cues
Description: Participants should walk in comfortable speed on the treadmill for 30 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training without auditory cues
Description: Participants should walk in comfortable speed on the treadmill for 30 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training without auditory cues
Description: Participants should walk in comfortable speed on the treadmill for 30 min.
Study: NCT01513148

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Superluminous light diode
Description: 900W, 880nm, 1.6 J/cm2 for 30sec

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superluminous light diode
Description: 900W, 880nm, 1.6 J/cm2 for 30sec
Study: NCT01249664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGF Trap-Eye (BAY86-5321)
Description: 1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Drug
Description: Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
Study: NCT06236737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor Exercise
Description: The sensorimotor group was given oculomotor, gaze stability and postural stability exercises. Each session lasted 40 minutes in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Exercise
Description: A flow was created for the yoga group. Each session lasting 40 minutes was included ocular motor, balance, meditation and stretching. Practices illustrated in table one were repeated for the eight weeks. Beginning of each session was focused on breathing exercises and the yoga flow is designed. Weeks 1-2. were prepared by focusing mostly on sagittal plane asanas. While 3-5. tweeks were focused on frontal plane asanas, 6-8. weeks were focused on transvers plan. Each session commenced with a 5-minute practice of a three dimensional breathing technique. This was followed by a 25-minute yoga asana flow, concluding with a 10-minute meditation in shavasana, also known as Corpse Pose. NDY was taught by an academician physiotherapist who has completed graduation in yoga therapy.
Study: NCT03102437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer Smart System
Description: The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
Study: NCT01481753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy without Braun enteroenterostomy
Description: no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Braun enteroenterostomy
Description: addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
Study: NCT03155841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills Coaching
Description: The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Resources
Description: The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
Study: NCT03812731

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
Study: NCT00198822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A or Beta-Carotene Supplements
Description: weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A or Beta-Carotene Supplements
Description: weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A or Beta-Carotene Supplements
Description: weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
Study: NCT02032732

Intervention type: OTHER
Intervention: leukocyte esterase test
Description: leukocyte esterase test on fluid removed by intra-articular aspiration

Intervention type: OTHER
Intervention: leukocyte esterase test
Description: leukocyte esterase test on fluid removed by intra-articular aspiration
Study: NCT02134158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tDCS and sham tDCS stimulations
Description: Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments.
Study: NCT04009863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echopulse
Description: Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radioactive iodine (Radioidine i131)
Description: Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
Study: NCT03797586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Description: Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture group
Description: Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
Study: NCT04081636

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Transrectal biopsy (TR-Bx)
Description: Through the rectum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Transrectal biopsy (TR-Bx)
Description: Through the rectum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systematic Transperineal biopsy (TP-Bx)
Description: Through the perineal skin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Transperineal biopsy (TP-Bx)
Description: Through the perineal skin
Study: NCT00698243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-027
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-027
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-027
Description: Administered orally
Study: NCT02820129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Wallet Card
Description: A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Reminder Card
Description: A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments.
Study: NCT02956603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine wire EMG electrodes
Description: Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine wire EMG electrodes
Description: Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine wire EMG electrodes
Description: Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
Study: NCT01152021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
Study: NCT02918383

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Indocyanin Green Dye (ICG)
Study: NCT04572477

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]THK-5351
Description: F-18 THK PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]THK-5351
Description: F-18 THK PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]AV-45
Description: F-18 AV45 PET Imaging

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]AV-45
Description: F-18 AV45 PET Imaging
Study: NCT03336021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAS program
Description: Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
Study: NCT00905736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcurrent treatment (controlled current)
Description: primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micocurrent treatment (controlled voltage)
Description: Microcurrent delivered for 6 hours daily for 3 weeks
Study: NCT04004650

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gluteal turnover flap
Description: Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
Study: NCT04141332

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG was recorded by EEG Machines
Description: EEG was recorded by EEG Machines

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG was recorded by EEG Machines
Description: EEG was recorded by EEG Machines
Study: NCT01549002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Fentanyl
Description: Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Morphine
Description: Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
Study: NCT01865409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Care
Description: Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
Study: NCT01824277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Pre-operative Diabetes Optimization
Description: Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
Study: NCT04113200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MerMed One
Description: A 1 kcal per ml enteral feed containing an alginate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nutricomp Soy Fibre
Description: A 1kcal per ml enteral feed not containing alginate.
Study: NCT00170287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICD Ablation plus VT-ablation
Description: ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Therapy
Description: ICD Therapy for the Treatment of unstable VT´s
Study: NCT00083031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT01439204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abatacept (BMS-188667)
Description: Solution for injection, Intravenous, 750 mg, Single dose, 1 day,

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept (BMS-188667)
Description: Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
Study: NCT01918839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VINCI Plus
Description: VINCI Plus 1ml injected into wrinkle treatment area

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane-L
Description: Restylane-L injected into wrinkle treatment area
Study: NCT01251367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: I.M. (intramuscular) injection on day 1 of each treatment cycle.
Study: NCT04326335

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Felt-tip marking
Description: Marking the location of the future stoma with a felt pen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Felt-tip marking + 3D printed ostomy button
Description: Marking the location of the future stoma with a felt pen + 3D printed ostomy button placed on the future stoma location
Study: NCT00997100

Intervention type: DRUG
Group type: OTHER
Intervention: paquinimod (ABR-215757)
Description: The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
Study: NCT01358409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
Study: NCT01441531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin 600 mg po
Description: Given one hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill given one hour before surgery
Description: Placebo pill given
Study: NCT01696240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil (Zydena)
Description: Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study: NCT00336973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Subcutaneous repeating dose
Study: NCT02114437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop TCI
Description: the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Opened-loop TCI
Description: the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
Study: NCT03594227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-501 400mg BID (Low dose)
Description: ATI-501 400mg BID oral low dose for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATI-501 600mg BID (Mid dose)
Description: ATI-501 600mg BID oral mid dose for oral administration